Results 121 to 130 of about 9,676 (179)

Highly replicating hepatitis C virus variants emerge in immunosuppressed patients causing severe disease. [PDF]

Nat Commun
Rothhaar P, Arand T, Seong HG, Heuss C, Tulessin M, Wang Z, Förster C, Schneider AC, Quistrebert J, Chai H, Reineke M, Benning L, Honegger J, Hofmann M, Thimme R, Timm J, STOPHCV investigators, Schnitzler P, Merle U, Shoukry NH, Bruneau J, Rodrigo C, Lloyd A, Bull RA, Ansari MA, Mogler C, McLauchlan J, Forns X, Pérez-Del-Pulgar S, Lohmann V.   +29 more
europepmc   +1 more source

Effect of the CSFV NS5A protein on key proteins in the MAPK and PI3K-mTOR signaling pathways in porcine macrophages. [PDF]

Front Microbiol
Wang Y, Zheng X, Yang Y, Zhao X, Li M, Huang J, Zhang Q, Qin X, Yu Y, Pan Q, Cao Z.   +10 more
europepmc   +1 more source

Characteristics of a Chinese Cohort of Patients with Chronic Hepatitis C Infection (2019-2023) and a Case Report of Resistance-associated Substitutions to Sofosbuvir-velpatasvir Treatment. [PDF]

J Clin Transl Hepatol
Xiong H, Pan S, Zhou C, Shi H, Xie Y, Guo J.   +5 more
europepmc   +1 more source

AlphaFold Prediction of Protein-Protein Interactions in the <i>Flaviviridae</i> Proteomes. [PDF]

Int J Mol Sci
Surya W, Goh J, Ponniah C, Torres J.
europepmc   +1 more source

Strategies of Classical Swine Fever Immune Evasion. [PDF]

Int J Mol Sci
Zhang Y, Li F, Liu Y.
europepmc   +1 more source

Structural bioinformatics approaches for predicting novel drug targets in hepatitis C virus proteins: a comprehensive analysis. [PDF]

Sci Rep
Qu M, Gao M, Sang X, Yu M, Guan Z, Chang W.   +5 more
europepmc   +1 more source

Reinfection and Resistance Associated Substitutions Following a Minimal Monitoring Approach for Hepatitis C Virus Treatment in MINMON Trial. [PDF]

Clin Infect Dis
Han WM, Solomon SS, Smeaton L, Avihingsanon A, Wagner Cardoso S, Li J, Parvangada A, Sulkowski M, Naggie S, Martin R, Mo H, Maiorova E, Wyles D.   +12 more
europepmc   +1 more source

Retreatment of patients with chronic hepatitis C, subtype 3a, and cirrhosis, who previously failed a regimen containing second-generation NS5A inhibitors with sofosbuvir + glecaprevir/pibrentasvir and ribavirin for 16-24 weeks. [PDF]

J Virol
Fedorchenko SV, Klimenko Z, Martynovich T, Solianyk I, Suprunenko T.   +4 more
europepmc   +1 more source

Computational design of potent dimeric phenylthiazole NS5A inhibitors for hepatitis C virus. [PDF]

Sci Rep
Liman W, Oubahmane M, Lahcen NA, Hdoufane I, Cherqaoui D, Daoud R, El Allali A.   +6 more
europepmc   +1 more source

Mechanisms and Therapeutic Strategies for HCV/HBV-Associated B-Cell Non-Hodgkin's Lymphomas: A Viewpoint. [PDF]

Oncol Res
Carloni G, Rinaldi M.
europepmc   +1 more source